<DOC>
	<DOCNO>NCT01282255</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate change disease activity follow 12 weekly s.c. ( skin ) dose NNC109-0012 compare placebo subject active Rheumatoid Arthritis ( RA ) .</brief_summary>
	<brief_title>Efficacy NNC109-0012 Subjects With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<criteria>Czech Republic : Age 18 65 year ( inclusive ) A diagnosis RA make least 3 month prior trial start Active RA Methotrexate treatment ( 7.5 mg 25 mg/week , inclusive ) least 12 week stable dose least 4 week prior trial start Female subject must willing avoid pregnancy breast feed throughout trial least 15 week follow last dose trial medication Male subject partner childbearing potential must willing use highly effective contraception throughout trial incl . 15 week follow periode Known suspect allergy trial product relate product Body Mass Index ( BMI ) low 18.5 high 35.0 kg/m^2 Subjects chronic inflammatory autoimmune disease RA ( except secondary Sj√∂gren 's syndrome stable hypothyroidism )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>